Please login to the form below

Not currently logged in
Email:
Password:

Jazz drug rejected by FDA advisors

Advisors to the US FDA have voted to recommend against the marketing approval of Jazz Pharmaceuticals' proposed new treatment for fibromyalgia

Advisors to the US Food and Drug Administration (FDA) have voted overwhelmingly to recommend that the federal agency not grant marketing approval to Jazz Pharmaceuticals' proposed new treatment for fibromyalgia.

At the joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, panellists voted 20-to-two to recommend that the New Drug Application (NDA) for JZP-6 (sodium oxybate) should be rejected due to concerns about the medicine's potential for abuse and misuse. Sodium oxybate is the sodium salt form of gamma-hydroxybutyrate, a potentially dangerous compound that is notoriously abused as a "date rape" drug.

Jazz has proposed a Risk Evaluation and Mitigation Strategy (REMS) that would tightly regulate the drug if it is approved.  The company already markets the narcolepsy drug Xyrem, which also contains sodium oxybate, under a REMS.

However, the panellists worried that because the fibromyalgia market is much larger than the narcolepsy market, the level of abuse of the fibromyalgia drug would also be greater. The narcolepsy drug is distributed through only one US pharmacy, while Jazz has proposed that the fibromyalgia drug would be distributed through 15 pharmacies to meet the larger demand.

A number of the FDA advisors urged Jazz to continue working on ways to ensure that the drug could be sold safely.

Some panellists also said that in order for approval to be feasible, Jazz would need to produce efficacy data showing that the drug was significantly more effective than three less-risky drugs already on the market for fibromyalgia: Pfizer's Lyrica (pregabalin), Eli Lilly's Cymbalta (duloxetine) and Forest Laboratories' Savella (milnacipran).

The FDA frequently follows its panellists' advice, but is not required by law to do so.

"While we are disappointed with the recommendation of the Joint Advisory Committee, we plan to work closely with FDA on the continuing review of our new drug application," said Bruce Cozadd, chairman and CEO of Jazz.

"We will carefully consider the input of the committee as we seek to address the needs of fibromyalgia patients for new treatment options in a safe and responsible way."

The NDA for JZP-6 was submitted in February of this year and contained results from two phase III clinical trials showing that sodium oxybate significantly decreased pain and fatigue, boosted daily functioning, and improved sleep quality for fibromyalgia patients. The studies also showed that the drug was well tolerated.

The FDA is aiming to make a decision on the NDA by October 11.

23rd August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....